- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02004223
Early Investigation of High Precision Radiotherapy Prior to Commencing Standard Radiotherapy for Prostate Cancer (BOOSTER)
Phase I Dose Escalation Study of Stereotactic BOOST for Prostate cancER
Current standard treatment for prostate cancer involves giving patients approximately 40 doses of radiotherapy, one dose per day over an 8 week period. The purpose of this study is to assess the effects of giving two separate high doses of a special type of precision radiotherapy to the prostate and then 5 weeks (instead of 8 weeks) of standard radiotherapy.
Hypothesis: It is safe to give patients an extra two doses of high-precision radiotherapy prior to commencing a shorter period of standard radiotherapy for prostate cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Prostate cancer accounts for one third of all new cancer diagnoses in men and approximately 30% of men will have External Beam Radiotherapy (EBRT) as primary local therapy. Local persistence of prostate cancer treated with radiotherapy is under-appreciated. Prostate cancer has a long natural history and the consequences of local persistence may not be realized for many years.
Prostate cancer has a slow growth with a potential doubling time ranging from weeks to months (median 42 days) which has led to the hypothesis that prostate cancer will behave more like a late reacting tissue(1). Brenner et al. (2) used data from prostate Low Dose Rate (LDR) permanent seed implants and EBRT series to derive an alpha/beta of approximately 1.5. Many groups have also calculated the alpha/beta ratio to be in the < 3.0 range(3).
If the alpha/beta ratio for prostate cancer is lower than the surrounding normal tissues (Brenner et al. have estimated the alpha/beta for the rectum to be over 5.0), doses greater than 2 Gy (hypofractionation) will afford an advantage as there will be a greater sensitivity of prostate cancer to radiation, as compared to the bladder or rectum. This benefit has been exploited for many years with High Dose Rate (HDR) brachytherapy using Iridium -192. Typical doses for HDR are 19Gy in two fractions in addition to 46Gy in 23 fractions of EBRT (4). With reference to our own institutional data from HDR brachytherapy we calculated the dose distribution in recently treated patients. Due to the nature of the iridium dose distribution, there are considerable areas of much higher dose delivered; 200% of the dose (38Gy) to 12.7% of the target volume, 150% (13.75Gy) to 32.6% of the target volume and 125% (11.9Gy) to 60.1% of the target. Despite the high doses to the periphery of the prostate it is possible to limit the dose to the rectum and bladder to 1cc < 75% (14.25Gy) and the 1cc urethra to <125% (23.75Gy) (4). HDR brachytherapy series have reported durable long term Biochemical Failure Free Survival (BFFS), which are as good or better than comparable external beam or surgical series(5). However despite the low toxicity and excellent biochemical outcomes, HDR brachytherapy utilization in Australia is low, with under 300 cases in total per year. This is due to the logistical difficulty of HDR brachytherapy, anaesthetic requirements, nursing care and patient discomfort.
There have been five published studies investigating stereotactic boost in addition to standard fractionation EBRT without using brachytherapy, four reports with the Cyberknife platform (6-9) and one with Intensity Modulated Radiotherapy (IMRT) (10). All of these series have early follow up (FU) with reported BFFS between 77% and 100%. The largest experience is from Katz et al. (8) who reported 73 patients with both intermediate (n= 41) and high risk (n=32) disease. They treated patients with the Cyberknife platform to deliver between 18 and 21 Gy in three fractions in addition to 45 Gy in 25 fractions EBRT. With a median follow up of 33 months, BFFS was 89.5% and 77.7% for the intermediate and high risk patients respectively. A 5 mm expansion from the prostate to the Planned Treatment Volume (PTV) was used except posteriorly, where the margin was 3mm. There was 7% Grade 2 acute genitourinary (GU) and gastrointestinal (GI) toxicity, with late Grade 2 estimates at three years of 5.5% (GU) and 8.2% (GI). Three other series using Cyberknife to mimic HDR were reported between 2008 and 2012 (6, 7, 9). These studies used margins of 0-2 mm posteriorly and 3-5 mm in other directions and reported low rates of Grade 2 and Grade 3 toxicity. Two of these reports specifically attempted to reproduce the heterogeneity of HDR with large areas of the PTV receiving >125% (40% to 45%) and >150% (5% to 10%) of the prescribed dose. Miralbell et al. (10) reported a Linac based IMRT boost in 50 patients in 2010. This series used an endorectal balloon but no image guidance, which may be the cause of their unacceptably high five year estimates of late GI Grade 2 toxicity of 26%.
Primary objective:
The primary study goal is to assess the acute toxicity of Stereotactic Body Radiotherapy (SBRT) boost with three increasing dose levels.
Secondary objectives:
- Nadir PSA at three months and over duration of follow-up
- Three year and five year Freedom From Biochemical Failure (FFBF) (Nadir + 2.0)
- Planning feasibility (Minor and Major planning violations)
- Late Gastrointestinal and Genitourinary Toxicity (modified Radiation Therapy Oncology Group (RTOG) scale)
- Patient reported QOL (EPIC-SF-12)
Hypothesis: It is safe to dose escalate prostate cancer treatment with a stereotactic boost of up to 30Gy in two fractions to the dominant nodule combined with external beam radiotherapy of 46Gy in 23 fractions with < 15% Grade 2 acute morbidity and < 5% Grade 3 acute morbidity.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
St Leonards, New South Wales, Australië, 2065
- Northern Sydney Cancer Centre, Royal North Shore Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Histologically proven prostate adenocarcinoma
- PSA obtained within three months prior to enrollment.
- International Prostate Symptom Score (I-PSS) score <15
- No contraindication to MRI (pacemaker, severe claustrophobia)
- Patient must be able to have fiducial markers placed in the prostate (if on anticoagulants, must be cleared by LMO or cardiologist).
- ECOG performance status 0-2
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Previous pelvic radiotherapy
- Prior total prostatectomy
- Unwilling or unable to give informed consent
- Unwilling or unable to complete quality of life questionnaires.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Dose escalation using stereotactic boost
Dose level allocation - Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level
|
This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level. The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified. Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Acute toxicity
Tijdsspanne: Assessed up to 12 weeks post treatment.
|
Portion of patients with grade 3 or greater genitourinary or gastrointestinal toxicity assessed using the Modified Radiation Therapy Oncology Group (RTOG) Toxicity Scale.
|
Assessed up to 12 weeks post treatment.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Late toxicity
Tijdsspanne: Up to five years
|
At a median follow up of 18 months, Kaplan Meir statistics will be used to estimate the 2 year late Gastrointestinal and Genitourinary Toxicity using the modified RTOG scale.
|
Up to five years
|
Cumulative toxicity rate:
Tijdsspanne: From the date of treatment completion assessed up to 5 years
|
The cumulative incidence of treatment related Grade 2 or higher GI or GU toxicity allowing for competing risk (death without prior toxicity event) and loss to follow up (censoring).
|
From the date of treatment completion assessed up to 5 years
|
Biochemical failure (PSA failure)
Tijdsspanne: Up to 5 years.
|
Nadir PSA at three months and over duration of follow-up. This will be compared to historical controls from our prospective database stratified by initial PSA and androgen deprivation use / duration (nil vs. short term vs. long term). When patients have reached a median follow-up of 24 months and 48 months, actuarial Kaplan Meir statistics will be used to estimate the 3 year and 5 year freedom from biochemical failure (FFBF) using the Nadir + 2.0 definition. |
Up to 5 years.
|
change in Quality of Life
Tijdsspanne: From baseline assessed up to 5 years.
|
Patient reported QOL using the validated EPIC SF-36 questionnaire will be collected at baseline, 3 months, 9 months and 21-24 months.
Analysis will be performed (a) using the mean scores, with a 10 point deterioration deemed clinically significant and (b) as a change from baseline per individual patient using the 21-24 month questionnaire.
A 10-20 point deterioration will be deemed mild-moderate and a >20 point deterioration will be deemed significant.
Kaplan Meir statistics will be used to estimate the proportion of patients with a ≥10 point, or ≥20 point deterioration at appropriate time points.
|
From baseline assessed up to 5 years.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 13-NSCCRO-P001
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Prostaatkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten